While Novogaia is building a next-gen discovery platform, CEO Tess Bevers emphasizes that the company's primary focus must be advancing its first drug candidates. For early-stage biotechs, the tangible value lies in getting molecules further down the pipeline, not just in perfecting the underlying technology.

The platform versus product debate is a false dichotomy. A true platform is a durable factory or 'flywheel' that repeatedly generates new, valuable products over time. This model requires sufficient capital and a genuinely enabling technology, not just a collection of similar assets.

CEO Jared Bauer applies a core lesson from his time at Apple to biotech: focus on the user experience, not the technical specifications. Instead of highlighting 'how fast the RAM is,' Apple focuses on what it enables, a principle he uses to guide product development.

Founders of platform technologies are often tempted to pursue many applications at once. A more effective strategy is to select and aggressively advance a single "beachhead program" to the clinic. This demonstrates the platform's value concretely, making it easier to attract funding and partners, while avoiding the dilution of resources.

To avoid the trap of being too broad, a platform company should deliberately focus R&D on capabilities that are game-changing and different from what's naturally available. This means prioritizing 'exotic' chemistries over replicating existing properties like hydrophobicity, ensuring genuine value creation.

The fundamental purpose of any biotech company is to leverage a novel technology or insight that increases the probability of clinical trial success. This reframes the mission away from just "cool science" to having a core thesis for beating the industry's dismal odds of getting a drug to market.

The venture creation strategy for platform biotechs isn't about finding one blockbuster drug. It's a binary bet: either the underlying scientific platform is sound and can repeatedly generate many medicines, or the entire concept fails. There is no middle ground of succeeding with just one product from the platform.

Gene therapy companies, which are inherently technology-heavy, risk becoming too focused on their platform. The ultimate stakeholder is the patient, who is indifferent to whether a cure comes from gene editing, a small molecule, or an antibody. The key is solving the disease, not forcing a specific technological solution onto every problem.

The future of biotech moves beyond single drugs. It lies in integrated systems where the 'platform is the product.' This model combines diagnostics, AI, and manufacturing to deliver personalized therapies like cancer vaccines. It breaks the traditional drug development paradigm by creating a generative, pan-indication capability rather than a single molecule.